John Tchelingerian is the founder of Promethera Biosciences. Promethera Biosciences has raised $132M in total funding. Latest round: Series D.
John Tchelingerian, PhD, is a biotech entrepreneur with a background in science, business, and deal-making. He joined Promethera Biosciences, a Belgian biotechnology company developing cell-based therapies for liver diseases, as Chairman of the Board in December 2014. Promethera Biosciences is developing Promethera® HepaStem for treating in-born errors of metabolism and acquired liver diseases. Tchelingerian has co-founded and managed several biotech companies including Neurotech, Key-Obs, and Diatos, and has raised over $100 million for his ventures.
Full founder directory · Investor directory · Company funding database · Fundraising library